LXRX Key Statistics, Chart & Performance
The current stock price of LXRX is 1.15 USD. In the past month the price decreased by -14.18%. In the past year, price increased by 45.83%.
LXRX Latest News, Press Relases and Analysis
LXRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.87 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.94 | 498.60B | ||
| MRK | MERCK & CO. INC. | 11.95 | 261.26B | ||
| PFE | PFIZER INC | 7.78 | 141.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.22 | 109.81B | ||
| ZTS | ZOETIS INC | 19.85 | 55.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 22.30B | ||
| VTRS | VIATRIS INC | 5.34 | 14.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.21B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.42B |
Related stock screener links
About LXRX
Company Profile
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 103 full-time employees. The company went IPO on 2000-04-07. The company is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The company has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. The company is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. The company is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
Company Info
LEXICON PHARMACEUTICALS INC
2445 Technology Forest Blvd, 11Th Floor
The Woodlands TEXAS 77381 US
CEO: Lonnel Coats
Employees: 103
Phone: 12818633000
LEXICON PHARMACEUTICALS INC / LXRX FAQ
What does LXRX do?
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 103 full-time employees. The company went IPO on 2000-04-07. The company is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The company has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. The company is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. The company is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
What is the stock price of LEXICON PHARMACEUTICALS INC today?
The current stock price of LXRX is 1.15 USD.
What is the dividend status of LEXICON PHARMACEUTICALS INC?
LXRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of LXRX stock?
LXRX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the next earnings date for LXRX stock?
LEXICON PHARMACEUTICALS INC (LXRX) will report earnings on 2026-03-04, after the market close.
Who owns LEXICON PHARMACEUTICALS INC?
You can find the ownership structure of LEXICON PHARMACEUTICALS INC (LXRX) on the Ownership tab.
LXRX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LXRX. When comparing the yearly performance of all stocks, LXRX is one of the better performing stocks in the market, outperforming 79.76% of all stocks.
LXRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LXRX. The financial health of LXRX is average, but there are quite some concerns on its profitability.
LXRX Financial Highlights
Over the last trailing twelve months LXRX reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS increased by 74.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.3% | ||
| ROE | -57.07% | ||
| Debt/Equity | 0.47 |
LXRX Forecast & Estimates
11 analysts have analysed LXRX and the average price target is 2.94 USD. This implies a price increase of 155.44% is expected in the next year compared to the current price of 1.15.
For the next year, analysts expect an EPS growth of 73.38% and a revenue growth 328.76% for LXRX